Data indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary circulating and emerging lineages More than five billion doses of the Pfizer-BioNTech COVID-19 vaccines distributed globallyVaccine demonstrates a favorable safety and efficacy profile Shipping will begin soon to ensure rapid access of this season’s vaccine  NEW YORK and MAINZ, GERMANY, July 29, 2026 - Pfizer Inc. (NYSE: PFE, 'Pfizer”) and BioNTech SE (Nasdaq: BNTX, 'BioNTech”) announced today that the European Commission (EC) has granted marketing authorization for the companies’ 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the Emergency Task Force (ETF) of the European Medicines Agency (EMA) to update COVID-19 vaccines to target the XFG variant of the JN.1 lineage for the 2026-2027 season. The ETF stated that 'the evidence suggests that targeting XFG would provide the best protection against COVID-19.”1